South Korea Epigenetics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents and Kits, Antibodies, ChiP-seq Kits, Bisulfite Conversion Kits, Whole Genome Amplification Kits, RNA Sequencing Kits, Others), By Technology (NDNA Methylation, Histone Methylation, Histone Acetylation, Large non-coding RNA, MicroRNA modification, Others), By Application (Oncology, Autoimmune Diseases, Metabolic Diseases, Cardiovascular Diseases, Others), By End Use (Academic Research, Clinical Research, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies) and Forecasts, 2026-2034

Last Updated: September 15, 2026 | Author: Debashree Bora | Format:

South Korea Epigenetics Market Size

The South Korea Epigenetics Market size was valued at USD 586 million in 2025 and is projected to grow from USD 651.10 million in 2026 to reach USD 1512.43 million by 2034, growing at a CAGR of 11.11% during the forecast period 2026–2034 .

In recent years, there has been a rise in the cases of chronic diseases like cancer, CVDs, and neurological disorders, amongst others, in the South Korean region, thereby driving the epigenetics market. There has also been a rise in the focus on personalized medicine and tailored therapeutics, which is estimated to create opportunities for market growth.

Market Key Takeaways

Global Market Size & Growth

Reagents and kits dominate the product segment

Oncology dominates the application segment

Pharmaceutical and biotechnology companies dominate the end-user segment

Download a Free Sample To learn more about this report.

Product Insights

The reagents and kits segment dominates the global epigenetics market. Reagents and kits dominate the product market due to their essential role in epigenetic research and diagnostics. They provide the necessary tools for conducting experiments and analyzing epigenetic modifications, facilitating advancements in understanding gene expression and disease mechanisms.

South Korea Epigenetics Market Size By Segments

Request Customizationto receive a tailored report.

Application Insights

The oncology segment is estimated to own the highest market share. The oncology segment is the largest application area in the South Korean epigenetics market, driven by the high prevalence of cancer. Epigenetic research in oncology focuses on understanding cancer mechanisms, identifying biomarkers for early detection, and developing precision therapies, significantly enhancing patient outcomes.

End-Users Insights

The pharmaceutical and biotechnology companies contributed to the largest market. Pharmaceutical and biotechnology companies in South Korea are pivotal to the epigenetics market, investing heavily in research and development to discover novel therapies and diagnostics. These companies leverage epigenetic mechanisms to develop targeted treatments for various diseases, particularly cancer.

South Korea Epigenetics Market Share By Segments

Speak to an Analystto discuss market opportunities.

Country Insights

Regionally, the South Korean epigenetics market is concentrated in major metropolitan areas such as Seoul, Gyeonggi-do, and Daejeon. As the capital city, Seoul hosts numerous leading academic institutions and research centers, making it a hub for biotechnology and epigenetic research. Gyeonggi-do, with its proximity to Seoul, also benefits from substantial investments and a concentration of biotech firms. Daejeon, home to the Daedeok Innopolis, a major R&D center, is another critical region contributing to market growth. There has also been a rise in research and development initiatives in the field of epigenetics, with ample positive findings.

For instance, the results of the skin epigenetics research conducted by the New Beauty Research Initiative (NBRI), operated by Amorepacific in collaboration with the Department of Dermatology at Johns Hopkins University School of Medicine, were presented at the 81st SID Annual Meeting held in Dallas, Texas, from May 15 to 17, 2024, entitled "Evaluation of epigenetic changes related to skin aging." Amorepacific's unique compounds, BioGF1K (Ginsenomics) and RE.D Flavonoid (Camellia extract), were used to research the epigenetic control of skin aging. When treated to skin cells isolated from the skin of patients aged 65 and 70 years with progressed photoaging, an epigenetic improvement effect was observed in approximately 60% of the 67,000 gene blocks. Such developments are estimated to boost the South Korean epigenetics market.

List of Key and Emerging Players in South Korea Epigenetics Market

Illumina Inc

Abcam Plc

Active Motif Inc

Agilent Technologies Inc

Hologic Inc

Zymo Research

Merck Millipore

PerkinElmer Inc

QIAGEN NV

Thermo Fisher Scientific Inc

and others

Key Industry Developments

June 2026

Illumina expanded its genomics and epigenomics portfolio in South Korea by strengthening collaborations with leading research institutes to accelerate multiomics research, biomarker discovery, and precision medicine applications.

May 2026

Thermo Fisher Scientific introduced an expanded portfolio of epigenetics research solutions, including advanced DNA methylation analysis and chromatin profiling workflows, supporting academic and clinical research laboratories across South Korea.

October 2025

QIAGEN launched new epigenetics sample preparation and methylation analysis solutions in the Asia-Pacific region, strengthening support for cancer research, translational medicine, and precision diagnostics in South Korea.

June 2025

Revvity expanded its epigenetics research portfolio by introducing enhanced next-generation sequencing library preparation and epigenomic analysis solutions for research institutions and biotechnology companies across South Korea.

Report Scope

Segmentation

By Product 8

Instruments
Reagents and Kits
Antibodies
ChiP-seq Kits
Bisulfite Conversion Kits
Whole Genome Amplification Kits
RNA Sequencing Kits
Others

By Technology 6

NDNA Methylation
Histone Methylation
Histone Acetylation
Large non-coding RNA
MicroRNA modification
Others

By Application 5

Oncology
Autoimmune Diseases
Metabolic Diseases
Cardiovascular Diseases
Others

By End Use 4

Academic Research
Clinical Research
Hospitals & Clinics
Pharmaceutical & Biotechnology Companies

Competitive Coverage Illumina Inc · Abcam Plc · Active Motif Inc · Agilent Technologies Inc · Hologic Inc

Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The South Korea Epigenetics Market was valued at USD 586 million in 2025.

The key players in the South Korea Epigenetics Market are Illumina Inc., Abcam Plc., Active Motif Inc., Agilent Technologies Inc., Hologic Inc., Zymo Research, Merck Millipore, PerkinElmer Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., and others.

The reagents and kits segment is the leading segment for the market during the forecast period.

Rising Prevalence of Cancer is the growth factor that drives the South Korea Epigenetics Market forward.

The surging focus on personalized medicine and precision healthcare represents a significant opportunity for the South Korean epigenetics market.

About the Author

Debashree Bora

Healthcare Lead

Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.
Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.